Pharma News

Researchers have uncovered the 3D structure of the nucleoprotein-RNA complex in the fatal Borna disease virus 1, paving the way for targeted antivirals.

Phase 3 NRG-GY019 trial results show letrozole monotherapy did not demonstrate non-inferiority to PC/L for progression-free survival in ovarian cancer.

Everest Medicines' subsidiary EverSea Medicines will acquire Hasten Biopharmaceuticals for $250m to enhance its commercial presence in the Asia Pacific.

ClearBridge Investments highlights Charles River Laboratories (CRL) as a key holding, positioned to benefit from recovering biotech funding and research.

The FDA and Commissioner Marty Makary propose permanently authorizing the rare pediatric disease priority review voucher program in the FY2027 budget.

Phase 1 trial data for TNX-4800, a human monoclonal antibody preventing Lyme disease, demonstrates safety, tolerability, and lasting pharmacokinetics.

Jeito Capital closes its second fund, Jeito II, surpassing its €1bn target to reach over $1.2bn for investing in clinical-stage biopharma companies.

NextCure receives FDA Fast Track Designation for SIM0505, a novel CDH6-targeted ADC for treating platinum-resistant ovarian cancer. Phase 1 data expected.

Foghorn Therapeutics will present new preclinical data for selective SMARCA2 inhibitor FHD-909 and degrader programs at the 2026 AACR Annual Meeting.

Researchers discovered that dermcidin, a natural antimicrobial peptide in the human body, exhibits antiviral activity against the influenza virus.

FDA issued a warning letter to ImmunityBio over misleading promotional claims about Anktiva, including overstated efficacy and omitted risks.

Mayo Clinic reported a dual-drug nanotherapy crossed the blood-brain barrier and improved survival in preclinical glioblastoma models.